Ois Podcast

Dompé, a family-owned global biopharmaceutical company with roots that date back over 150 years, built its legacy by following two principles: take calculated risks, and focus on need rather than precedent.Georgea Pasedis, PharmD, RPh, Dompé’s Senior Vice President and Global Head of Medical Affairs, moved into her current role by following similar principles. After earning her PharmD and practicing at the renowned Mass Eye and Ear in Boston, Dr. Psedis determined she could make a broader impact by transitioning to industry.In her medical affairs role, Dr. Pasedis discusses the science behind Dompé’s products with physicians worldwide. That education includes intel on rhNGF (recombinant human Nerve Growth Factor), the protein that forms the basis for Oxervate (cenegermin-bkbj) the first FDA-approved treatment for neurotrophic keratitis (NK).With podcast host Paul Karpecki, OD, FAAO, Dr. Pasedis discusses the mechanism of action behind Oxervate and how it helps both early- and late-stage NK patients.She also d